A Phase 2 interventional study of CsA high dose and CsA low dose in Allergic Conjunctivitis, sponsored by Fovea Pharmaceuticals SA. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-09.
Sponsored by Fovea Pharmaceuticals SA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 3rd largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2010, is one of 25 in phase 2, and was the 30th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 716 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Fovea Pharmaceuticals SA is the lead sponsor of 4 studies on the registry; none are open to participants now.
Fovea Pharmaceuticals SA has 2 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
Drug: CsA low dose · Drug: PA
Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
Drug: CsA high dose · Drug: PA
Administration of a solution of Cyclosporine (high dose) and Placebo
Drug: CsA high dose · Drug: Placebo
Administration of a solution of Cyclosporine (low dose) and Placebo
Drug: CsA low dose · Drug: Placebo
Administration of a suspension of Prednisolone Acetate and Placebo
Drug: PA
Administration of Placebo
Drug: Placebo
Solution of Cyclosporine (high dose) administered during 28 days
Solution of Cyclosporine (low dose) administered during 28 days
Suspension of Prednisolone Acetate administered during 28 days
Placebo solution administered during 28 days
Diary assessment of signs and symptoms of ocular allergy
Patient-reported ocular itching and redness
Time frame: During the 28 days of treatment
Diary and office assessments of various ocular and nasal allergy signs and symptoms
Patient-reported ocular itching and redness, lid swelling, tearing and nasal itching Investigator assessments of ocular redness and chemosis
Time frame: During 28 days of treatment
Safety
Ocular tolerance and adverse events
Time frame: During the 28 days of treatment
The record gives a start of May 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fovea Pharmaceuticals SA